TriangleViPOR Combination (NCT03223610)
ViPOR Combination trial for Relapsed/Refractory B-Cell Lymphoma (NCT03223610). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for B cell lymphoma that has returned or not improved after treatment, in adults 18 and older.
The idea: combine five drugs. ViPOR is a combination that includes venetoclax and ibrutinib. In the first part, drugs are added in steps to study safety and find a dose. Later patients all receive the full combination for six cycles.
The study began in 2018 and plans 155 patients. At the National Institutes of Health Clinical Center in Bethesda, Christopher Melani leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.